Naomi Haas, MD

Naomi Haas, MD, discusses the 5-year follow-up of the KEYNOTE-564 study being presented at the 2025 ASCO Annual Meeting.

Naomi B. Haas, MD, discusses the choice of frontline treatment for favorable-risk patients with advanced clear cell renal cell carcinoma.

Naomi B. Haas, MD, discusses how patient characteristics and preference influence the choice of frontline treatment for advanced clear cell renal cell carcinoma.

Naomi B. Haas, MD, discusses the use of VEGF tyrosine kinase inhibitors as neoadjuvant therapy for renal cell carcinoma.

Naomi Haas, MD, discusses the current areas of ongoing research in the treatment landscape for patients with prostate cancer.

Naomi Haas, MD, discusses the importance of using PSMA, an antigen that is expressed on the cell surface, for the detection of prostate cancer.